Expression of MiR-608 in Nonsmall Cell Lung Cancer and Molecular Mechanism of Apoptosis and Migration of A549 Cells

Objective. This Work is aimed at exploring the effect of microRNA (MiR)-608 on the function of nonsmall cell lung cancer (NSCLC) A549 cells and related mechanisms. Methods. Blood samples of 106 NSCLC patients (experimental group) as well as 124 normal people (control group) were selected for relevant investigation. Polymerase chain reaction (PCR) as well as DNA sequencing was used to determine the genotyping of the MiR-608 rs4919510 polymorphism. MiR-608 expression in cells was detected by real-time PCR technology. Western blotting was used to detect changes in protein levels. NSCLC tissues as well as adjacent tissues were explored in 33 patients undergoing surgery. Results. MiR-608 rs4919510 does not influence the incidence of NSCLC patients. In addition, MiR-608 expression was downregulated in the tumor tissue of NSCLC patients, while the transcription factor activating enhancer-binding protein 4 (TFAP4) expression was upregulated. MiR-608 promotes DOX- (Doxorubicin-) induced apoptosis by negatively regulating TFAP4 expression in NSCLC tissue. TFAP4 can significantly inhibit the migration of A549 cells. Conclusion. The findings in this investigation can contribute to the effective treatment of NSCLC patients. Also, the investigation can provide some theoretical support for the application of new targets for NSCLC treatment.
Objective. This Work is aimed at exploring the effect of microRNA (MiR)-608 on the function of nonsmall cell lung cancer (NSCLC) A549 cells and related mechanisms. Methods. Blood samples of 106 NSCLC patients (experimental group) as well as 124 normal people (control group) were selected for relevant investigation. Polymerase chain reaction (PCR) as well as DNA sequencing was used to determine the genotyping of the MiR-608 rs4919510 polymorphism. MiR-608 expression in cells was detected by real-time PCR technology. Western blotting was used to detect changes in protein levels. NSCLC tissues as well as adjacent tissues were explored in 33 patients undergoing surgery. Results. MiR-608 rs4919510 does not influence the incidence of NSCLC patients. In addition, MiR-608 expression was downregulated in the tumor tissue of NSCLC patients, while the transcription factor activating enhancer-binding protein 4 (TFAP4) expression was upregulated. MiR-608 promotes DOX- (Doxorubicin-) induced apoptosis by negatively regulating TFAP4 expression in NSCLC tissue. TFAP4 can significantly inhibit the migration of A549 cells. Conclusion. The findings in this investigation can contribute to the effective treatment of NSCLC patients. Also, the investigation can provide some theoretical support for the application of new targets for NSCLC treatment.
12 22 2020 1 8 8824519 8824519 Taishan Scholar Program of Shandong Province ts201712087 National Natural Science Foundation of China http://dx.doi.org/10.13039/501100001809 81672292 https://creativecommons.org/licenses/by/4.0/ 10.1155/2020/8824519 https://www.hindawi.com/journals/bmri/2020/8824519/ http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.pdf http://downloads.hindawi.com/journals/bmri/2020/8824519.xml 10.1158/0008-5472.CAN-16-3556 10.1001/jamaoncol.2017.4427 10.21037/tlcr.2016.06.07 10.1097/PAI.0000000000000531 10.1186/s12943-018-0897-7 10.18632/oncotarget.19197 10.1016/j.drudis.2019.06.010 10.1002/jcp.27788 10.1038/s41419-017-0218-x 10.1016/j.gene.2017.04.007 10.1016/j.biopha.2018.06.073 10.18632/oncotarget.13072 10.1038/s41374-018-0164-y Journal of BUON Z. Jin 22 2 474 2017 Serum expression level of miR-504 can differentiate between glioblastoma multiforme and solitary brain metastasis of non-small cell lung carcinoma 10.26355/eurrev_201808_15629 10.3892/ijo.2017.4174 10.3892/mmr.2019.10616 10.3389/fgene.2019.00809 10.1097/PAP.0000000000000161 10.1002/cncy.21937